Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR800 IAB2M
- Development stage
- Unknown
- Lead developer
- ImaginAb
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IR800 IAB2M is an investigational intraoperative fluorescence imaging agent designed for real-time visualization of prostate cancer during surgical procedures. It consists of a humanized anti-PSMA (Prostate-Specific Membrane Antigen) minibody, known as IAB2M, conjugated to the near-infrared (NIR) fluorescent dye IRDye 800CW. The IAB2M minibody is an 80 kDa antibody fragment that targets the extracellular domain of PSMA, a protein frequently overexpressed on the surface of prostate cancer cells. When administered intravenously prior to robot-assisted laparoscopic radical prostatectomy (RARP), the agent enables surgeons to identify tumor margins, extracapsular extension, and pelvic lymph node involvement using NIR imaging platforms. Developed by ImaginAb in collaboration with the University of Oxford, IR800 IAB2M aims to improve surgical precision and oncological outcomes in patients with high-risk prostate cancer.
- Other names
- IRDye 800CW-IAB2MIRDye800CW-IAB2MIRDye-800CW-IAB2MIAB2M-IR800IAB-2M-IR800IAB 2M-IR800
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on IR800 IAB2M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IR800 IAB2M.